The purpose of this legislation is to ensure that the review process for human drugs and medical devices can continue even during government shutdowns or lapses in funding. It aims to prevent delays in getting important medical innovations to patients by allowing the Food and Drug Administration (FDA) to accept applications and submissions even when the usual funding mechanisms are not in place. The key provisions of this legislation include special rules for handling drug and device submissions during a lapse in appropriations.